Literature DB >> 3125981

Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo.

L Ossowski1.   

Abstract

We have previously shown that inhibition of uPA activity of a human tumor-HEp3-results in a drastic reduction of its metastasis in the chick embryo. Using 125IUdR-labeled tumor cells, we have now studied the role of uPA in individual steps of tumor metastasis. We found that, 48 hr after inoculation of tumor cells on the CAM, the organs of the embryos, inoculated with cells in which uPA was inhibited, contained 4-fold less cells than the controls. Neither the initial advance of the tumor mass into the CAM nor the process of extravasation was affected by the inhibition of tumor uPA. However, the infiltration of the CAM mesenchyme by individual tumor cells was blocked when tumor uPA activity or production was inhibited. In addition, indirect evidence implicated uPA as an essential factor in the tumor cell intravasation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125981     DOI: 10.1016/s0092-8674(88)80025-4

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  45 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2.

Authors:  S S Lakka; S D Konduri; S Mohanam; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.

Authors:  J H Axelrod; R Reich; R Miskin
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

Review 4.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

5.  Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model.

Authors:  M R Gyetko; G H Chen; R A McDonald; R Goodman; G B Huffnagle; C C Wilkinson; J A Fuller; G B Toews
Journal:  J Clin Invest       Date:  1996-04-15       Impact factor: 14.808

6.  Expression and localization of urokinase-type plasminogen activator in human spinal column tumors.

Authors:  Z L Gokaslan; S K Chintala; J E York; V Boyapati; S Jasti; R Sawaya; G Fuller; D M Wildrick; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

7.  The c-myc-regulated gene mrl encodes plasminogen activator inhibitor 1.

Authors:  G C Prendergast; L E Diamond; D Dahl; M D Cole
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

8.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

Authors:  T J de Vries; P H Quax; M Denijn; K N Verrijp; J H Verheijen; H W Verspaget; U H Weidle; D J Ruiter; G N van Muijen
Journal:  Am J Pathol       Date:  1994-01       Impact factor: 4.307

9.  Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases.

Authors:  S M Bell; D C Connolly; N J Maihle; J L Degen
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

10.  Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.

Authors:  C Festuccia; V Dolo; F Guerra; S Violini; P Muzi; A Pavan; M Bologna
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.